A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

Also called NCT05110846

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05110846
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05110846. Randomized; quadruple masking; primary purpose treatment. Start 2022-02-22 (actual); primary completion 2023-02-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus
Condition
Obesity
Condition
Overweight
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Placebo
Intervention (Drug)
CT-868
Lead sponsor
Carmot Therapeutics, Inc. (class: industry)
Collaborator
Hoffmann-La Roche (class: industry)

Record details

Record id
cardio:ct-nct05110846
Content hash
f84d9692d77ce802bff6a2597324d377b35b30feb9238e1f9d717e233c44ecf7